Sales Update 2025 (in Englisch) (sales update jan 25)

‌Sales update 2025

January 2026

‌Galenica Group

Strong sales growth despite one sales day less

Net sales (in million CHF)

1,900

2,021

+5.0%

1,995

+5.9%

2,140

3,921

+5.5%

4,136

H1 2024 H2 2024 2024 H1 2025 H2 2025 2025

‌Galenica Group

Sales growth supported by acquisition of Labor Team

Net sales (in million CHF)

+5.5%

3'921

4'136

+4.8%

3'180

3'333

+6.8%

1'700

1'816

2024
2025

Galenica Group Products & Care Logistics & IT

‌Galenica Group

Sales growth across all business areas

‌Pharmacies Omni-Channel

Strong sales growth with prescription medicines

Net sales (in million CHF)

1,404

+4.9%

1,473

Portfolio of local pharmacies expanded by 5 locations: expansion impact1 of +1.6%

+5.2%

678

727

713

+4.6%

760

Generics substitution rate remains with 78.1% at high level (79.2% at Dec 2024).

H1 2024 H2 2024 2024 H1 2025 H2 2025 2025

1. The effect of net expansion is calculated only including point of sales without a full year period comparison (acquisitions, openings and closure of pharmacies)

‌Products & Brands

Growth dampend by bridging stock sales in prior year

Net sales (in million CHF)International Swiss market

100 90

24 17

190

+2.1%

+0.7% +3.7%

101 93

21

194

-12.6%

+6.2%

Swiss market:

− Growth due to expansion of +6.1%1

− Organic growth of CH +0.1%

− Growth of CH market sales2 -0.6%

− Market share2 of 10.7%

H1 2024 H2 2024 2024 H1 2025 H2 2025 2025

1. Expansion impact related new licence agreements in Jan. 2025, the effect of net expansion is calculated only including business activities without a full year period comparison (acquisitions and new license agreements)

2. Product sales to end customers of Verfora, Spagyros and Padma products (like-for-like, streetprices), IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, Consumer Health market YTD Dec. 2025

‌Services & Production

Strong sales growth in homecare business

Net sales (in million CHF)

+4.3% +3.8%

56

60

58

62

115

+4.0%

120

H1 2024 H2 2024 2024 H1 2025 H2 2025 2025

Consistent, strong growth with services for homecare organizations and nursing homes

‌Wholesale

Further Market share gains in pharmacies segments

Net sales (in million CHF)Physicians
Pharmacies
Others

1,496 1,609

435 464

972 1'055

3,105

900

2,028

+4.8%

+5.6% +4.2%

1,580 1,676

461 474

1'027 1'109

3,255

934

2,136

+3.9%

+5.3%

89 89 178 92 93

185

+3.8%

H1 2024 H2 2024 2024 H1 2025 H2 2025 2025

‌Logistics & IT Services

Solid growth with Prewholesale

Net sales (in million CHF)

+2.8%

39

39

+1.8%

39

+3.8%

40

77 80

H1 2024 H2 2024 2024 H1 2025 H2 2025 2025

Solid growth with prewholesale distribution

‌Swiss pharmaceutical market

Strong growth despite one sales day less

in million CHF

760

740

720

700

680

660

640

620

600

580

560

540

520

500

Jan Feb Mrz Apr Mai Jun Jul Aug Sep Okt Nov Dez

2023 2024 2025 ‌Swiss pharmaceutical market December 2025 Hospitals

CHF 1,959.3 million (+5.0%)

15.5 million packs (-0.1%)

24.3%

Drugstores

CHF 61.0 million (-3.3%)

5.7 million packs (-4.6%)

0.8%

26.5%

43.5%

Local Pharmacies

CHF 3,512.4 million (+5.3%)

132.3 million packs (+0.7%)

Physicians

CHF 2,140.8 million (+3.9%)

45.5 million packs (+0.2%)

5.0%

Mail-order Pharmacies

CHF 399.8 million (+9.3%)

1.8 million packs (-3.7%)

‌Consumer healthcare market December 2025

2.9%

12.6%

19.3%

65.2%

OTC

-0.3%

Personal care

-1.9%

Patient care

+1.2%

Nutrition

-1.1%

Non-medication segment

-0.8%

Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices

© IQVIA - Consumer Health market December 2025

‌Disclaimer

Disclaimer Galenica

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward- looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted develop-ments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

Disclaimer IQVIA © 2026, IQVIA AG

All rights reserved. The information may not be duplicated, stored, processed further, nor be made accessible in whole or in part to any third party without prior express and valid written permission of IQVIA AG. Terms used in connection with data/figures such as "patient", "doctor", "medical practice", "prescriber", or "pharmacy" do not designate any personal data but exclusively anonymous information (according to applicable, valid data protection laws).

IQVIA utilizes highly sophisticated technologies and methods in order to ensure that all its Information Services meet the applicable data protection requirements, regardless of the way data are combined.